The European Commission has recently issued a series of important decisions regarding the authorisation of specific chemicals under the REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) Regulation. These decisions, outlined in documents C/2023/917 and C/2023/901, are pivotal for various industries, particularly in medical and scientific research sectors.
Under these decisions, authorisation has been granted for the use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (‘4-tert-OPnEO’) and 4-Nonylphenol, branched and linear, ethoxylated (4-NPnEO). These substances are now authorised for use in buffer solutions for a range of applications, including the production of purified proteins and quality control testing in laboratories. Such applications are essential in scientific research, development, and in vitro diagnostic procedures.
The authorisations have been granted to several companies, including Phadia GmbH, Thermo Fisher Scientific Baltics UAB, and Brahms GmbH. Additionally, RSI ChemRep Europe Ltd, representing OraSure Technologies Inc., has received authorisation for using 4-tert-OPnEO as a surfactant in in-vitro diagnostic device developer solutions for diagnosing Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV).
These decisions were made in accordance with Article 60(4) of the REACH Regulation, which states that the socio-economic benefits of using these substances outweigh the potential risks to human health and the environment. This highlights the European Commission's commitment to balancing the advancement of scientific and medical research with the need to protect health and the environment.
The review period for these authorisations is set until 4 January 2033, providing a significant duration for monitoring and evaluating the use of these substances. This period also allows for the potential development of safer and more environmentally friendly alternatives.
For companies in the chemical and pharmaceutical industries, understanding and adhering to these regulations is crucial. Foresight, with its deep expertise in chemical legislation, offers tailored solutions to assist businesses in navigating these complex regulatory environments. Our services ensure compliance with current regulations and prepare companies for future legislative changes, thereby reducing risks and enhancing operational effectiveness.
Stay informed about the latest in chemical legislation and discover how Foresight can support your compliance and risk management strategies by visiting our blog, Signal.
The European Commission has recently issued a series of important decisions regarding the authorisation of specific chemicals under the REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) Regulation. These decisions, outlined in documents C/2023/917 and C/2023/901, are pivotal for various industries, particularly in medical and scientific research sectors.
Read this article now for free!
You have read 3 articles.
This is some text inside of a div block.
Trusted by professionals at
